Huntington’s disease (HD) is a progressive neurodegenerative disorder that prominently affects the basal ganglia, leading to affective, cognitive, behavioral, and motor decline. The primary site of neuron loss in HD is the striatal part of the basal ganglia, with GABAergic medium size spiny neurons (MSNs) being nearly completely lost in advanced HD.
Objective:
Based on the hypothesis that mutant huntingtin (mHTT) protein injures neurons via transcriptional dysregulation, we set out to establish a transcriptional profile of HD disease progression in the well characterized transgenic mouse model, R6/2, and two Knock-in models (KI); zQ175KI (expressing mutant mouse/human chimeric Htt protein) and HdhQ200 HET KI (carrying one allele of expanded mouse CAG repeats).
Methods:
In this study, we used quantitative PCR (qPCR) to evaluate striatal mRNA levels of markers of neurotransmission, neuroinflammation, and energy metabolism.
Results:
After analyzing and comparing transcripts from pre-symptomatic and symptomatic stages, markers expressed in the basal ganglia MSNs, which are typically involved in maintaining normal neurotransmission, showed a genotype-specific decrease in mRNA expression in a pattern consistent with human studies. In contrast, transcripts associated with neuroinflammation and energy metabolism were mostly unaffected in these animal models of HD.
Conclusion:
Our results show that transcripts linked to neurotransmission are significantly reduced and are consistent with disease progression in both zQ175KI and R6/2 transgenic mouse models.
RossCA, MargolisRL, RosenblattA, RanenNG, BecherMW, AylwardE. Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA). Medicine (Baltimore). 1997;76(5):305–38.
2.
KegelKB, MeloniAR, YiY, KimYJ, DoyleE, CuiffoBG, et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem. 2002;277(9):7466–76.
3.
Luthi-CarterR, HansonSA, StrandAD, BergstromDA, ChunW, PetersNL, et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: Parallel changes in muscle and brain. Hum Mol Genet. 2002;11(17):1911–26.
4.
RossCA. Polyglutamine pathogenesis: Emergence of unifying mechanisms for Huntington’s disease and related disorders. Neuron. 2002;35(5):819–22.
5.
ChaJH. Transcriptional signatures in Huntington’s disease. Prog Neurobiol. 2007;83(4):228–48.
6.
KuhnA, GoldsteinDR, HodgesA, StrandAD, SengstagT, KooperbergC, et al. Mutant huntingtin’s effects on striatal gene expression in mice recapitulate changes observed in human Huntington’s disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet. 2007;16(15):1845–61.
7.
PerutzM. Polar zippers: Their role in human disease. Protein Sci. 1994;3(10):1629–37.
LiSH, ChengAL, ZhouH, LamS, RaoM, LiH, et al. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol. 2002;22(5):1277–87.
10.
HanssonO, GuatteoE, MercuriNB, BernardiG, LiXJ, CastilhoRF, et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci. 2001;14(9):1492–504.
11.
MangiariniL, SathasivamK, SellerM, CozensB, HarperA, HetheringtonC, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493–506.
12.
CarterRJ, LioneLA, HumbyT, MangiariniL, MahalA, BatesGP, et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci. 1999;19(8):3248–57.
13.
MenalledLB, KudwaAE, MillerS, FitzpatrickJ, Watson-JohnsonJ, KeatingN, et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175. PLoS One. 2012;7(12):e49838.
LinCH, Tallaksen-GreeneS, ChienWM, CearleyJA, JacksonWS, CrouseAB, et al. Neurological abnormalities in a knock-in mouse model of Huntington’s disease. Hum Mol Genet. 2001;10(2):137–44.
16.
SathasivamK, NeuederA, GipsonTA, LandlesC, BenjaminAC, BondulichMK, et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A. 2013;110(6):2366–70.
17.
ZhengZ, DiamondMI. Huntington disease and the huntingtin protein. Prog Mol Biol Transl Sci. 2012;107:189–214.
18.
BennCL, FoxH, BatesGP. Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington’s disease. Mol Neurodegener. 2008;3:17.
19.
GotoS, HiranoA, Rojas-CoronaRR. An immunohistochemical investigation of the human neostriatum in Huntington’s disease. Ann Neurol. 1989;25(3):298–304.
20.
Seto-OhshimaA, EmsonPC, LawsonE, MountjoyCQ, CarrascoLH. Loss of matrix calcium-binding protein-containing neurons in Huntington’s disease. Lancet. 1988;1(8597):1252–5.
21.
WeeksRA, PicciniP, HardingAE, BrooksDJ. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington’s disease. Ann Neurol. 1996;40(1):49–54.
22.
GlassM, FaullRL, DragunowM. Loss of cannabinoid receptors in the substantia nigra in Huntington’s disease. Neuroscience. 1993;56(3):523–7.
23.
AlbinRL, QinY, YoungAB, PenneyJB, ChesseletMF. Preproenkephalin messenger RNA-containing neurons in striatum of patients with symptomatic and presymptomatic Huntington’s disease: An in situ hybridization study. Ann Neurol. 1991;30(4):542–9.
24.
RaymondLA, AndreVM, CepedaC, GladdingCM, MilnerwoodAJ, LevineMS. Pathophysiology of Huntington’s disease: Time-dependent alterations in synaptic and receptor function. Neuroscience. 2011;198:252–73.
25.
NorrisPJ, WaldvogelHJ, FaullRL, LoveDR, EmsonPC. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington’s disease. Neuroscience. 1996;72(4):1037–47.
26.
MassouhM, WallmanMJ, PourcherE, ParentA. The fate of the large striatal interneurons expressing calretinin in Huntington’s disease. Neurosci Res. 2008;62(4):216–24.
van RossumD, HanischUK. Microglia. Metab Brain Dis. 2004;19(3-4):393–411.
29.
PaveseN, GerhardA, TaiYF, HoAK, TurkheimerF, BarkerRA, et al. Microglial activation correlates with severity in Huntington disease: A clinical and PET study. Neurology. 2006;66(11):1638–43.
30.
TaiYF, PaveseN, GerhardA, TabriziSJ, BarkerRA, BrooksDJ, et al. Imaging microglial activation in Huntington’s disease. Brain Res Bull. 2007;72(2-3):148–51.
31.
HertzL, ZhaoZ, ChenY. The astrocytic GABA(A)/benzodiazepine-like receptor: The Joker receptor for benzodiazepine-mimetic drugs?Recent Pat CNS Drug Discov. 2006;1(1):93–103.
32.
RusH, CudriciC, DavidS, NiculescuF. The complement system in central nervous system diseases. Autoimmunity. 2006;39(5):395–402.
33.
BonifatiDM, KishoreU. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol. 2007;44(5):999–1010.
34.
GasqueP, DeanYD, McGrealEP, VanBeekJ, MorganBP. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology. 2000;49(1-2):171–86.
35.
SinghraoSK, NealJW, MorganBP, GasqueP. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington’s disease. Exp Neurol. 1999;159(2):362–76.
36.
BjorkqvistM, WildEJ, ThieleJ, SilvestroniA, AndreR, LahiriN, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J Exp Med. 2008;205(8):1869–77.
37.
DalrympleA, WildEJ, JoubertR, SathasivamK, BjorkqvistM, PetersenA, et al. Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res. 2007;6(7):2833–40.
38.
BouchardJ, TruongJ, BouchardK, DunkelbergerD, DesrayaudS, MoussaouiS, et al. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington’s disease. J Neurosci. 2012;32(50):18259–68.
39.
BrowneSE, BealMF. The energetics of Huntington’s disease. Neurochem Res. 2004;29(3):531–46.
40.
TabriziSJ, CleeterMW, XuerebJ, TaanmanJW, CooperJM, SchapiraAH. Biochemical abnormalities and excitotoxicity in Huntington’s disease brain. Ann Neurol. 1999;45(1):25–32.
41.
TabriziSJ, WorkmanJ, HartPE, MangiariniL, MahalA, BatesG, et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol. 2000;47(1):80–6.
42.
SorollaMA, Reverter-BranchatG, TamaritJ, FerrerI, RosJ, CabiscolE. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med. 2008;45(5):667–78.
43.
PerluigiM, PoonHF, MaragosW, PierceWM, KleinJB, CalabreseV, et al. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: A model of Huntington disease. Mol Cell Proteomics. 2005;4(12):1849–61.
44.
ChangKH, ChenYC, WuYR, LeeWF, ChenCM. Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington’s disease patients. PLoS One. 2012;7(9):e46492.
